Improving the effectiveness of psychological interventions for depression and anxiety in the cardiac rehabilitation pathway using group-based metacognitive therapy (PATHWAY Group MCT): Study protocol for a randomised controlled trial

Trials

Volumn 19, Issue 1, 2018, Pages

  Wells, Adrian ^a   McNicol, Kirsten ^a   Reeves, David ^b   Salmon, Peter ^c,d   Davies, Linda ^b   Heagerty, Anthony ^a,b   Doherty, Patrick ^e   McPhillips, Rebecca ^a   Anderson, Rebecca ^a   Faija, Cintia ^a   Capobianco, Lora ^a   Morley, Helen ^b   Gaffney, Hannah ^f   Shields, Gemma ^b   Fisher, Peter ^c,d  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY OF YORK   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Anxiety; Cardiac rehabilitation; Depression; Group therapy; Heart disease; Metacognitive therapy; Psychological intervention; Rumination; Worry

Indexed keywords

ADULT; ANXIETY; ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE SEVERITY; EMOTIONAL STRESS; GROUP THERAPY; HEALTH ECONOMICS; HEART DISEASE; HEART REHABILITATION; HUMAN; MENTAL HEALTH; MULTICENTER STUDY; POSTTRAUMATIC STRESS DISORDER; PSYCHOLOGICAL WELL-BEING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THINKING; UNITED KINGDOM; COGNITIVE BEHAVIORAL THERAPY; COST BENEFIT ANALYSIS; ECONOMICS; ENGLAND; HEALTH CARE COST; METACOGNITION; MULTICENTER STUDY (TOPIC); PROCEDURES; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME FACTOR; TREATMENT OUTCOME;

ANXIETY; CARDIAC REHABILITATION; COGNITIVE BEHAVIORAL THERAPY; COST-BENEFIT ANALYSIS; DEPRESSION; ENGLAND; HEALTH CARE COSTS; HEART DISEASES; HUMANS; MENTAL HEALTH; METACOGNITION; MULTICENTER STUDIES AS TOPIC; PSYCHOTHERAPY, GROUP; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 85044844739     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-018-2593-8     Document Type: Article

References (64)

1. National Audit of Cardiac Rehabilitation. Annual Report. York: British Heart Foundation, University of York; 2012. http://www.cardiacrehabilitation.org.uk/docs/2012.pdf. Accessed 6 Sept 2017
2. NHS Scotland. Cardiac Rehabilitation in Scotland. 2013. http://www.isdscotland.org/Health-Topics/Heart-Disease/Publications/. Accessed 22 July 2017.
3. NHS England. Increase Uptake of Cardiac Rehabilitation for People with Coronary Artery Disease and Following Acute Heart Failure. 2014. https://www.england.nhs.uk/wp-content/uploads/2014/02/pm-fs-3-10.pdf. Accessed 22 July 2017.
4. Edmondson D, Richardson S, Falzon L, Davidson KW, Mills MA, Neria Y. Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: A meta-analytic review. PLoS One. 2012;7:e38915. https://doi.org/10.1371/journal.pone.0038915.
5. Meijer A, Conradi HJ, Bos EH, Thombs BD, van Melle JP, de Jonge P. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: A meta-analysis of 25 years of research. Gen Hosp Psychiatry. 2011;33(3):203-16. https://doi.org/10.1016/j.genhosppsych.2011.02.007.
6. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: A meta-analysis. Psychosom Med. 2004;66(6):802-13. https://doi.org/10.1097/01.psy.0000146332.53619.b2.
7. Dickens C, Cherrington A, McGowan L. Depression and health-related quality of life in people with coronary heart disease: A systematic review. Eur J Cardiovasc Nurs. 2012;11(3):265-75. https://doi.org/10.1177/1474515111430928.
8. Baumeister H, Haschke A, Munzinger M, Hutter N, Tully PJ. Inpatient and outpatient costs in patients with coronary artery disease and mental disorders: A systematic review. BioPsychoSoc Med. 2015;9:11. https://doi.org/10.1186/s13030-015-0039-z.
9. Frasure-Smith N, Lespérance F, Gravel G, Masson A, Juneau M, Talajic M, Bourassa MG. Depression and health-care costs during the first year following myocardial infarction. Psychosom Res. 2000;48(4):471-8. https://doi.org/10.1016/S0022-3999(99)00088-4.
10. Reese RL, Freedland KE, Steinmeyer BC, Rich MW, Rackley JW, Carney RM. Depression and rehospitalization following acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2011;4(6):626-33. https://doi.org/10.1161/CIRCOUTCOMES.111.961896.
11. Naylor C, Parsonage M, McDaid D, Knapp M, Fossey M, Galea A. Long-Term Conditions and Mental Health: The Cost of Comorbidities. London: The King's Fund and Centre for Mental Health; 2012. http://www.kingsfund.org.uk/publications/long-term-conditions-and-mental-health. Accessed 22 July 2017
12. O'Neil A, Sanderson K, Oldenburg B. Depression as a predictor of work resumption following myocardial infarction (MI): A review of recent research evidence. Health Qual Life Outcomes. 2010;8(1):95. https://doi.org/10.1186/1477-7525-8-95.
13. Department of Health. Commissioning Pack for Cardiac Rehabilitation. London: Department of Health; 2010. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/Browsable/DH_117504. Accessed 6 Sept 2017
14. rd Edition). UK: BACPR; 2017. http://www.bacpr.com/resources/BACPR_Standards_and_Core_Components_2017.pdf. Accessed 6 Sept 2017
15. HM Government. No Health without Mental Health: A Cross-Government Mental Health Outcomes Strategy for People of All Ages. London: Department of Health; 2011. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213761/dh_124058.pdf. Accessed 6 Sept 2017
16. National Institute for Health and Clinical Excellence. Depression in Adults with a Chronic Physical Health Problem: Recognition and Management. London: National Institute for Health and Clinical Excellence; 2009. https://www.nice.org.uk/Guidance/CG91. Accessed 6 Sept 2017
17. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev. 2011;9:CD008012. https://doi.org/10.1002/14651858.CD008012.pub3.
18. Dickens C, Cherrington A, Adeyemi I, Roughley K, Bower P, Garrett C, Bundy C, Coventry P. Characteristics of psychological interventions that improve depression in people with coronary heart disease: A systematic review and meta-regression. Psychosom Med. 2013;75(2):211-21. https://doi.org/10.1097/PSY.0b013e31827ac009.
19. Dowlati Y, Herrmann N, Swardfager WL, Reim EK, Lanctot KL. Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: A meta-analysis. Can J Psychiatr. 2010;55(2):91-9. https://doi.org/10.1177/070674371005500205.
20. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011;107(7):972-9. https://doi.org/10.1016/j.amjcard.2010.11.017.
21. Rutledge T, Redwine L, Linke SE, Mills PJ. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med. 2013;75(4):335-49. https://doi.org/10.1097/PSY.0b013e318291d798.
22. O'Neil A, Sanderson K, Oldenburg B, Taylor CB. Impact of depression treatment on mental and physical health-related quality of life of cardiac patients: A meta-analysis. J Cardiopulm Rehabil Prev. 2011;31(3):146-56. https://doi.org/10.1097/HCR.0b013e3181fc0985.
23. Wells A. Metacognitive therapy: Cognition applied to regulating cognition. Behav Cogn Psychother. 2008;36:651-8. https://doi.org/10.1017/S1352465808004803.
24. Wells A, Matthews G. Modelling cognition in emotional disorder: The S-REF model. Behav Res Ther. 1996;34:881-8. https://doi.org/10.1016/S0005-7967(96)00050-2.
25. Cook SA, Salmon P, Dunn G, Holcombe C, Cornford P, Fisher P. A prospective study of the association of metacognitive beliefs and processes with persistent emotional distress after diagnosis of cancer. Cognit Ther Res. 2015;39(1):51-60. https://doi.org/10.1007/s10608-014-9640-x.
26. Maher-Edwards L, Fernie BA, Murphy G, Nikcevic AV, Spada MM. Metacognitive factors in chronic fatigue syndrome. Clin Psychol Psychother. 2012;19:552-7. https://doi.org/10.1002/cpp.757.
27. Trick L, Watkins E, Windeatt S, Dickens C. The association of perseverative negative thinking with depression, anxiety and emotional distress in people with long-term health conditions: A systematic review. J Psychosom Res. 2016;91:89-101. https://doi.org/10.1016/j.jpsychores.2016.11.004.
28. Wells A. Metacognitive Therapy for Anxiety and Depression. London: Guilford Press; 2009.
29. Hjemdal O, Hagen R, Solem S, Nordahl H, Kennair L, Ryum T, Nordahl HM, Wells A. Metacognitive therapy in major depression: An open trial of comorbid cases. Cogn Behav Pract. 2016;24(3):312-8. https://doi.org/10.1016/j.cbpra.2016.06.006.
30. Hagen R, Hjemdal O, Soelm S, Kennair LEO, Nordahl HM, Fisher P, Wells A. Metacognitive therapy for depression in adults: A waiting list randomized controlled trial with six months follow-up. Front Psychol. 2017;8:31. https://doi.org/10.3389/fpsyg.2017.00031.
31. Papageorgiou C, Wells A. Group metacognitive therapy for severe antidepressant and CBT resistant depression: A baseline-controlled trial. Cognit Ther Res. 2015;39(1):14-22. https://doi.org/10.1007/s10608-014-9632-x.
32. van der Heiden C, Melchior K. A 30-Month follow-up of generalized anxiety disorder status after metacognitive therapy and Intolerance of uncertainty therapy. Eur J Pers Cent Healthc. 2014;2(4):434-8. https://doi.org/10.5750/ejpch.v2i4.812.
33. van der Heiden C, Muris P, van der Molen HT. Randomized controlled trial on the effectiveness of metacognitive therapy and intolerance-of-uncertainty therapy for generalized anxiety disorder. Behav Res Ther. 2012;50(2):100-9. https://doi.org/10.1016/j.brat.2011.12.005.
34. Wells A, Fisher P, Myers S, Wheatley J, Patel T, Brewin CR. Metacognitive therapy in recurrent and persistent depression: A multiple-baseline study of a new treatment. Cognit Ther Res. 2009;33:291-300. https://doi.org/10.1007/s10608-007-9178-2.
35. Wells A, Walton D, Lovell K, Proctor D. Metacognitive therapy versus prolonged exposure in adults with chronic post-traumatic stress disorder: A parallel randomised controlled trial. Cognit Ther Res. 2015;39:70-80. https://doi.org/10.1007/s10608-014-9636-6.
36. Normann N, van Emmerik AAP, Morina N. The efficacy of metacognitive therapy for anxiety and depression: A meta-analytic review. Depress Anxiety. 2014;31(5):402-11. https://doi.org/10.1002/da.22273.
37. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-70. https://doi.org/10.1111/j.1600-0447.1983.tb09716.x.
38. Fergus TA, Bardeen JR. The metacognitions Questionnaire-30: An examination of a bifactor model and measurement invariance among men and women in a community sample. Assessment. 2017; https://doi.org/10.1177/1073191116685807.
39. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52:69-77. https://doi.org/10.1016/S0022-3999(01)00296-3.
40. Weiss DS, Marmar CR. The Impact of Event Scale-Revised. In: Wilson JP, Leane TM, editors. Assessing Psychological Trauma and PTSD. New York: Guildford Press; 1997. p. 399-411.
41. Wells A, Cartwright-Hatton S. A short form of the metacognitions questionnaire: Properties of the MCQ-30. Behav Res Ther. 2004;42(4):385-96. https://doi.org/10.1016/S0005-7967(03)00147-5.
42. Fergus TA, Bardeen JR, Orcutt HK. Attentional control moderates the relationship between activation of the cognitive attentional syndrome and symptoms of psychopathology. Personal Individ Differ. 2012;53:213-7. https://doi.org/10.1016/j.paid.2012.03.017.
43. Spada MM, Mohiyeddini C, Wells A. Measuring metacognitions associated with emotional distress: Factor structure and predictive validity of the Metacognitions Questionnaire 30. Personal Individ Differ. 2008;45:238-42. https://doi.org/10.1016/j.paid.2008.04.005.
44. Herman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of the EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727-36. https://doi.org/10.1007/s11136-011-9903-x.
45. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes. 2010;8:13. https://doi.org/10.1186/1477-7525-8-13.
46. Devlin, N., Shah, K., Feng, Y., Mulhern, B. and Van Hout B. Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England Office of Health Economics. 2016. https://www.ohe.org/publications/valuing-health-related-quality-life-eq-5d-5l-value-set-england. Accessed 13 Sept 2017.
47. National Institute for Health and Care Excellence. Position Statement on the use of the EQ-5D-5L Valuation Set. NICE. 2017. https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisal-guidance/eq5d5l_nice:position_statement.pdf. Accessed 13 Sept 2017.
48. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708-15. https://doi.org/10.1016/j.jval.2012.02.008.
49. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Clinical Excellence; 2013. https://www.nice.org.uk/process/pmg9/chapter/foreword. Accessed 7 Sept 2017
50. Boeije HA. Purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36(4):391-409. https://doi.org/10.1023/A:1020909529486.
51. Glaser B, Strauss A. The Discovery of Grounded Theory. New York: Aldine Publishing Company; 1967.
52. StataCorp. Stata Statistical Software. Release, vol. 14. StataCorp LP: College Station; 2015.
53. Stiles WB. Evaluating qualitative research. Evid Based Ment Health. 1999;2:99-101. https://doi.org/10.1136/ebmh.2.4.99.
54. Kincheloe JL, McLaren P. Rethinking critical theory and qualitative research. In: Denzin NK, Lincoln YS, editors. Handbook of Qualitative Research, vol. 2. London: Sage; 2000. p. 279-314.
55. Department of Health. NHS Reference Costs. 2016. https://www.gov.uk/government/collections/nhs-reference-costs. Accessed 13 Sept 2017.
56. Personal Social Services Research Unit. Unit Costs of Health and Social Care. http://www.pssru.ac.uk/project-pages/unit-costs/. Accessed 13 Sept 2017.
57. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEconomics. 2014;32(12):1157-70. https://doi.org/10.1007/s40273-014-0193-3.
58. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1-503. https://doi.org/10.3310/hta19140.
59. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold. PharmacoEconomics. 2008;26(9):733-44. https://doi.org/10.2165/00019053-200826090-00004.
60. National Institute for Health and Care Excellence. Carrying NICE over the Threshold. National Institute for Health and Care Excellence. 2015. https://www.nice.org.uk/news/blog/carrying-nice-over-the-threshold. Accessed 13 Sept 2017.
61. Office of Health Economics. OHE Occasional Paper Critiques the Claxton et al. 13,000 Per QALY Estimate. Office of Health Economics. 2015. https://www.ohe.org/news/ohe-occasional-paper-critiques-claxton-et-al-13000-qaly-estimate. Accessed 13 Sept 2017.
62. Raftery JP. NICE's cost-effectiveness range: Should it be lowered? PharmacoEconomics. 2014;32(7):613-5. https://doi.org/10.1007/s40273-014-0158-6.
63. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ. 2004;329(7459):224-7. https://doi.org/10.1136/bmj.329.7459.224.
64. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. ISPOR health economic evaluation publication guidelines-CHEERS good reporting practices task force. Consolidated health economic evaluation reporting standards (CHEERS)--explanation and elaboration: A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231-50. https://doi.org/10.1016/j.jval.2013.02.002.